Insulin degludec/insulin aspart biosimilar (22011)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Insulin degludec/insulin aspart biosimilar (22011), covering 2023-04-07 to 2023-04-07. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China [Phase 3]